White & Case advises Merck KGaA on agreement to acquire life science company Mirus Bio for US$600 million

Press Release
1 min read

Global law firm White & Case LLP has advised Merck KGaA, Darmstadt, Germany (MKDG), a leading science and technology company, on the agreement to acquire life science company Mirus Bio for US$600 million.

Mirus Bio is a US specialist in the development and commercialization of transfection reagents. Transfection reagents play a key role in the production of viral vectors for cell and gene therapies. The acquisition will advance MKDG’s integrated offering for viral vector manufacturing und complements the existing portfolio for development and production of novel modalities like cell and gene therapies. Novel modalities are a key growth area for MKDG’s life science business sector.

The transaction with Gamma Biosciences, a life sciences platform established by global investment firm KKR for the acquisition of Mirus Bio, is expected to close in the third quarter of 2024 and is subject to regulatory clearance and other customary closing conditions.

The White & Case team which advised on the transaction was led by partners Stefan Koch (Frankfurt) and Caitlin Powell Gimpel (New York) and included partners Strati Sakellariou-Witt (Brussels), Anna Kertesz, Farhad Jalinous (both Washington, DC) and David Dreier (New York), local partner Mathias Bogusch (Frankfurt), counsel Ryan Brady, Jason Burgoyne, Ajita Shukla (all Washington, DC) and Samantha Rozell (Chicago) and associates Kai Neumann, Michael Grambow (both Frankfurt), Francesco Balestra (Milan), Giuseppe Tantulli (Brussels, Milan), Allain Andry, Naari Ha, Tyrone Crawford (all Washington, DC), Rucha Phadtare (New York) and Aron Senoner (Brussels).

Press contact
For more information please speak to your local media contact.